Analysis of Efficacy and Safety in Patients Aged 65–75 Years at Randomization | Zendy

H. A. W. Neil | Zendy; David A. DeMicco | Zendy; Don Luo | Zendy; D. J. Betteridge | Zendy; Helen M. Colhoun | Zendy; Paul N. Durrington | Zendy; Shona Livingstone | Zendy; John Fuller | Zendy; G. A. Hitman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Analysis of Efficacy and Safety in Patients Aged 65–75 Years at Randomization

Author(s) -

H. A. W. Neil,

David A. DeMicco,

Don Luo,

D. J. Betteridge,

Helen M. Colhoun,

Paul N. Durrington,

Shona Livingstone,

John Fuller,

G. A. Hitman

Publication year - 2006

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc06-0872

Subject(s) - medicine , atorvastatin , diabetes mellitus , placebo , randomization , relative risk , type 2 diabetes , absolute risk reduction , myocardial infarction , clinical endpoint , post hoc analysis , stroke (engine) , statin , randomized controlled trial , confidence interval , endocrinology , mechanical engineering , alternative medicine , pathology , engineering

Rates of cardiovascular disease are highest in the elderly. Lipid-lowering statin therapy reduces the proportional risk as effectively in older patients as in younger individuals; however, limited data are available for elderly patients with type 2 diabetes. We conducted a post hoc analysis to compare the efficacy and safety of atorvastatin among 1,129 patients aged 65-75 years at randomization with 1,709 younger patients in the Collaborative Atorvastatin Diabetes Study (CARDS).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research